Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pharvaris N.V.
< Previous
1
2
3
Next >
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at the GA²LEN UCARE Conference 2023
November 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
November 15, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
November 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the 18th German Allergy Congress
September 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
August 23, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
July 21, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
June 26, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces $70 Million Private Placement Financing
June 20, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
June 10, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Annual Meeting of Shareholders
June 01, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
May 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
April 05, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
March 18, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present in Upcoming March Investor Conferences
March 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
February 24, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at SVB Securities Global Biopharma Conference
February 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
January 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
December 08, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks
December 08, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
November 10, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
October 07, 2022
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
